This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Green Cross Corporation

Drug Names(s): GC-1111, biobetter idursulfase beta

Description: Hunterase is a biobetter version of idursulfase (a recombinant human iduronate-2-sulfatase (IDS)), and is an enzyme replacement therapy. It acts by providing the enzyme for uptake into cellular lysosomes which leads to cellular internalization of the enzyme and subsequent catabolism of accumulated glycosaminoglycans (GAG) that gets accumulated due to missing or defective iduronate-2-sulfatase in mucopolysaccharidosis.

In a preclinical comparison with Elaprase, Hunterase had higher formylglycine content and, correspondingly, greater enzyme activity. It also had greater uptake into normal human fibroblasts.

Hunterase News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug